Parkinson's disease psychosis: presentation, diagnosis and management
- PMID: 29160144
- DOI: 10.2217/nmt-2017-0028
Parkinson's disease psychosis: presentation, diagnosis and management
Abstract
Parkinson's disease is a neurodegenerative disorder characterized by motor and nonmotor symptoms. Psychosis is a common feature of Parkinson's disease. Parkinson's disease psychosis (PDP) encompasses minor phenomena (illusions, passage hallucinations and presence hallucinations), visual and nonvisual hallucinations and delusions. PDP is associated with reduced function and quality of life. The initial management approach should focus on identification and treatment of any contributory medical factors, reduction or discontinuation of medications with potential to induce or worsen psychosis, nonpharmacological strategies and consideration of acetylcholinesterase inhibitor treatment in the setting of dementia. Pimavanserin, quetiapine and clozapine may all be considered for use in PDP. In this review, we discuss the presentation, diagnosis and management of PDP.
Keywords: Parkinson's disease; antipsychotic; delusions; hallucinations; pimavanserin; psychosis.
Similar articles
-
Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.Expert Rev Clin Pharmacol. 2017 Nov;10(11):1161-1168. doi: 10.1080/17512433.2017.1369405. Epub 2017 Oct 17. Expert Rev Clin Pharmacol. 2017. PMID: 28817967 Review.
-
Comprehensive identification of delusions and olfactory, tactile, gustatory, and minor hallucinations in Parkinson's disease psychosis.Parkinsonism Relat Disord. 2018 Sep;54:40-45. doi: 10.1016/j.parkreldis.2018.04.008. Epub 2018 Apr 4. Parkinsonism Relat Disord. 2018. PMID: 29653909
-
Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.Ann Pharmacother. 2017 Jun;51(6):479-487. doi: 10.1177/1060028017693029. Epub 2017 Feb 1. Ann Pharmacother. 2017. PMID: 28375643 Review.
-
Parkinson's disease and Parkinson's disease psychosis: a perspective on the challenges, treatments, and economic burden.Am J Manag Care. 2017 Apr;23(5 Suppl):S83-S92. Am J Manag Care. 2017. PMID: 28715903 Review.
-
Psychosis in Parkinson's Disease: Looking Beyond Dopaminergic Treatments.Curr Pharm Des. 2022;28(33):2725-2741. doi: 10.2174/1381612828666220428102802. Curr Pharm Des. 2022. PMID: 36321314 Review.
Cited by
-
Retrospective analyses evaluating the mortality risk associated with pimavanserin or other atypical antipsychotics in patients with Parkinson disease psychosis.Clin Park Relat Disord. 2024 May 6;10:100256. doi: 10.1016/j.prdoa.2024.100256. eCollection 2024. Clin Park Relat Disord. 2024. PMID: 38770047 Free PMC article. Review.
-
HOMER1 Polymorphism and Parkinson's Disease-Psychosis: Is there an Association?Ann Indian Acad Neurol. 2024 Mar-Apr;27(2):178-182. doi: 10.4103/aian.aian_1038_23. Epub 2024 Apr 17. Ann Indian Acad Neurol. 2024. PMID: 38751916 Free PMC article.
-
Analysis of Medicare Patients Treated with Pimavanserin versus Other Atypical Antipsychotics: A Cost-Offset Model Evaluating Skilled Nursing Facility Stays and Long-Term Care Admissions in Parkinson's Disease Psychosis.Clinicoecon Outcomes Res. 2024 Mar 11;16:149-159. doi: 10.2147/CEOR.S452162. eCollection 2024. Clinicoecon Outcomes Res. 2024. PMID: 38495124 Free PMC article.
-
Fabricating Polymer/Surfactant/Cyclodextrin Hybrid Particles for Possible Nose-to-Brain Delivery of Ropinirole Hydrochloride: In Vitro and Ex Vivo Evaluation.Int J Mol Sci. 2024 Jan 18;25(2):1162. doi: 10.3390/ijms25021162. Int J Mol Sci. 2024. PMID: 38256239 Free PMC article.
-
Inflammation in Metal-Induced Neurological Disorders and Neurodegenerative Diseases.Biol Trace Elem Res. 2024 Jan 11. doi: 10.1007/s12011-023-04041-z. Online ahead of print. Biol Trace Elem Res. 2024. PMID: 38206494 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical